Natera and Pirche AG have entered into a collaboration to link Pirche's pre-transplant immunological risk assessment with Natera's Prospera test for post-transplant molecular monitoring. The companies plan to showcase this integrated approach to transplant care at the 2026 American Transplant Congress, where new clinical data on Prospera's role in prognosis and immunosuppression management will also be presented. Natera, trading at $234.76, has seen a 36.6% return over the past year and a 15.5% gain over the past month. The partnership aims to connect pre-transplant risk analytics with Prospera monitoring in a single data-driven workflow, potentially influencing clinical adoption and competitive positioning in the transplant diagnostics space.
Natera IncPartnership integrates pre-transplant risk assessment with Prospera monitoring, enhancing product offering and clinical adoption.
Collaboration links Pirche's pre-transplant risk assessment with Natera's Prospera, expanding its platform's utility.